The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience

Table 1

Characteristics of inflammatory bowel disease patients on infliximab with concerns for loss of response at time of therapeutic drug monitoring.

	Low IFX/high ADA ()	Low IFX/low ADA ()	Therapeutic IFX ()
Gender, male	2 (66.7%)	16 (64.0%)	19 (44.2%)
Age, years (range)	42 (31–63)	37 (19–81)	38 (19–68)
UC	1 (33.3%)	12 (48.0%)	14 (32.6%)
CD	2 (66.7%)	13 (52.0%)	29 (67.4%)
Disease duration, months ± SD	112 ± 86	110 ± 98	160 ± 101
Baseline partial Mayo Score ± SD	3.0 ± 0	4.7 ± 1.4	4.4 ± 2.0
Baseline Harvey-Bradshaw Score ± SD	3.5 ± 2.1	5.9 ± 4.3	6.7 ± 4.3
Objective evidence of disease	3 (100%)	17 (68.0%)	25 (58.1%)
Infliximab duration, months ± SD	25 ± 24	27 ± 28	45 ± 32
Concomitant immunosuppression	0 (0%)	10 (40.0%)	9 (20.9%)